Use of platelet-rich plasma for COVID-19-related olfactory loss: a randomized controlled trial.

ABSTRACT:

Introduction

The current study evaluated the use of platelet-rich plasma (PRP), an autologous blood product with supraphysiologic concentrations of growth factors, in the treatment of prolonged coronavirus disease 2019 (COVID-19)-related smell loss.

Methods

This multi-institutional, randomized controlled trial recruited patients with COVID-19 who had objectively measured smell loss (University of Pennsylvania Smell Identification Test [UPSIT] ≤ 33) between 6 and 12 months. Patients were randomized to three intranasal injections of either PRP or sterile saline into their olfactory clefts. The primary outcome measure was change in Sniffin' Sticks score (threshold, discrimination, and identification [TDI]) from baseline. The secondary end point measures included responder rate

SUBMITTER: Yan CH 

PROVIDER: S-EPMC9877663 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature